TABLE 5.
Pooled risk estimates of safety outcomes from randomized controlled trials of therapy against invasive fungal infection (aspergillosis versus candidiasis)
| Infection | Total no. of patients included | % of patients with: |
|||||
|---|---|---|---|---|---|---|---|
| Treatment discontinuation due to adverse effects |
Elevation of liver enzyme levels requiring of stopping treatment |
Elevation of liver enzyme levels not requiring stopping of treatment |
|||||
| Pooled estimate | 95% CI | Pooled estimate | 95% CI | Pooled estimate | 95% CI | ||
| Aspergillosis | 866 | 16.5 | 5.0-27.9 | 1.1 | 0-3.4 | 12.4 | 2.1-22.8 |
| Candidiasis | 2,708 | 6.1 | 3.7-8.5 | 1.1 | 0.4-1.8 | 7.2 | 4.3-10.2 |